Incyte Net Cash Flow 2010-2025 | INCY

Incyte net cash flow for the twelve months ending March 31, 2025 was $-5.408B, a 735.98% decline year-over-year.

  • Incyte annual net cash flow for 2024 was $-1.526B, a 682.13% decline from 2023.
  • Incyte annual net cash flow for 2023 was $0.262B, a 70.68% decline from 2022.
  • Incyte annual net cash flow for 2022 was $0.894B, a 64.21% increase from 2021.

Incyte Net Cash Flow 2010-2025 | INCY

  • Incyte annual net cash flow for 2024 was $-1.526B, a 682.13% decline from 2023.
  • Incyte annual net cash flow for 2023 was $0.262B, a 70.68% decline from 2022.
  • Incyte annual net cash flow for 2022 was $0.894B, a 64.21% increase from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$220.6B
Amgen (AMGN)$158.8B
Gilead Sciences (GILD)$136.4B
Vertex Pharmaceuticals (VRTX)$120.4B
Bristol Myers Squibb (BMY)$95.4B
GSK (GSK)$78.4B
CSL (CSLLY)$76.6B
Regeneron Pharmaceuticals (REGN)$61.3B
Alnylam Pharmaceuticals (ALNY)$41.1B
Argenex SE (ARGX)$34.3B
BioNTech SE (BNTX)$27.1B
Royalty Pharma (RPRX)$20.2B
Biogen (BIIB)$19.7B
Insmed (INSM)$18.6B
Illumina (ILMN)$15.7B
Genmab (GNMSF)$14.2B
Genmab (GMAB)$13.7B
Moderna (MRNA)$13B
Exelixis (EXEL)$12.2B
BioMarin Pharmaceutical (BMRN)$11.1B
QIAGEN (QGEN)$10.7B
Ascendis Pharma (ASND)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.4B
Exact Sciences (EXAS)$9.8B
Verona Pharma American Depositary Share (VRNA)$8.9B
Bio-Techne Corp (TECH)$8.5B
Blueprint Medicines (BPMC)$8.4B
Roivant Sciences (ROIV)$7.7B
Repligen (RGEN)$7.3B
Regencell Bioscience Holdings (RGC)$7.3B